1. National Institute for Health and Clinical Excellence (NICE): Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of NICE technology appraisal guidance 111, NICE technology appraisal guidance 217). 2011, London (UK): National Institute for Health and Clinical Excellence (NICE), (accessed on July 5th 2011), [ http://www.nice.org.uk/guidance/TA217 ]
2. Drug Commission of the German Medical Association: Dementia. Drug prescription in practice. Therapeutic guidelines of the Drug Commission of the German Medical Association (in German). 2004, http://www.akdae.de/Arzneimitteltherapie/TE/Archiv/Demenz.pdf Accessed: 2011-07-09. (Archived by WebCite® at http://www.webcitation.org/602utmyNL )
3. German Society for Psychiatry and Psychotherapy and German Society for Neurology: S3-Guideline Dementias (in German). 2009, http://media.dgppn.de/mediadb/media/dgppn/pdf/leitlinien/s3-leitlinie-demenz-lf.pdf . Accessed: 2011-07-09. (Archived by WebCite® at http://www.webcitation.org/602v301Xg )
4. IQWiG: Cholinesterase inhibitors in Alzheimer's disease. Final report A05-19A. 2007, Cologne: Institute for Quality and Efficiency in Health Care (IQWiG)
5. Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, Booker L, Oremus M: Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med. 2008, 148: 379-97.